Drug review highlights sulopenem’s efficacy in treating uUTI in women, indicating broader potential against resistant bacteria.
To describe and analyze the pharmacodynamic and pharmacokinetic properties, and clinical evidence supporting the use of sulopenem etzadroxil and probenecid. In October 2024, the Food and Drug Administration (FDA) approved sulopenem etzadroxil and probenecid for the treatment of uncomplicated urinary tract infections (uUTI) in adult women. This review describes the use of sulopenem for the treatment of uUTI, complicated UTI, and intra-abdominal infections compared to antimicrobials commonly utilized in practice for a specific infectious disease. Sulopenem is an effective and safe treatment option for the treatment of uUTI in adult women, however current research lacks the evidence to confidently recommend sulopenem for other infectious diseases.
No takes yet. Share an insight, caveat, or question.
Ocheretyaner et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: